# Council Decision of 20 November 2012 on the conclusion of a Protocol to the Euro-Mediterranean Agreement establishing an association between the European Communities and their Member States, of the one part, and the State of Israel, of the other part, on Conformity Assessment and Acceptance of Industrial Products (CAA) (2013/1/EU), Division 2: Exclusions


Medicinal products derived from human blood or human plasma, advanced therapy medicinal products, investigational medicinal products, homoeopathic medicinal products, medicinal gases and veterinary immunologicals are excluded from the coverage of this Annex.
The possibility of extending the coverage of this Annex to medicinal products derived from human blood or human plasma, investigational medicinal products and veterinary immunologicals shall be discussed by the Parties two years from the entry into force of this Annex.

---
Source: https://www.legislation.gov.uk/eudn/2013/1/schedule/ANNEX/division/ON MUTUAL ACCEPTANCE OF INDUSTRIAL PRODUCTS/division/SECTION II/division/2. (the official version)
Page: https://openlegislation.uk/eu-decision-2013-1/schedule-ANNEX/division-ON MUTUAL ACCEPTANCE OF INDUSTRIAL PRODUCTS/division-SECTION II/division-2.
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.